Oxford Biodynamics
- Company typePublic
- Founded2007
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
Oxford Biodynamics firmographics
Firmographics- Name
- Oxford Biodynamics
- Legal name
- Oxford BioDynamics PLC
- Website
- https://oxfordbiodynamics.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Oxford Biodynamics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Reference & Esoteric Testing Laboratories (HLAFAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Oxford Biodynamics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices5 records
Markets served
Oxford Biodynamics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Test Sales: Revenue generated from the sale of clinical diagnostic tests (EpiSwitch PSE, EpiSwitch CiRT) to healthcare providers, hospitals, and clinicians. Tests are sold directly to registered physicians with results delivered as reports for clinical decision-making.
- Pharmaceutical Partnerships: Revenue from collaborations with pharmaceutical companies for companion diagnostics, clinical trial biomarker services, and potential co-development of targeted therapies using the EpiSwitch platform.
- Research Tools and Services: EpiSwitch Explorer array kit and Orion platform services sold to researchers and drug developers for genomic analysis and biomarker discovery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | EpiSwitch diagnostic tests sold to healthcare providers |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
Oxford Biodynamics product offering
Product offeringCore offering
Oxford BioDynamics develops and commercializes clinical diagnostic tests based on its proprietary EpiSwitch 3D genomics platform, which measures chromatin conformation signatures in blood samples to predict cancer likelihood, immunotherapy response, and disease diagnosis. The company sells blood-based diagnostic tests (EpiSwitch PSE, CiRT, ME/CFS) to healthcare providers and offers research tools (EpiSwitch Orion, Explorer Array Kit) for pharmaceutical and academic partners.
Product overview
Oxford BioDynamics offers a portfolio of clinical smart tests based on its proprietary EpiSwitch 3D genomics platform. The company has two commercially available products: EpiSwitch PSE for prostate cancer detection (94% accuracy when combined with PSA testing) and EpiSwitch CiRT for predicting checkpoint inhibitor immunotherapy response (85% accuracy). Additional products include EpiSwitch ME/CFS for chronic fatigue syndrome diagnosis and EpiSwitch Orion for research applications. The EpiSwitch Platform serves as the underlying technology powering all diagnostic tests, enabling 3D genome regulation analysis for precision medicine at scale.
Differentiator
Problem solved
Functional benefit
Brands
- EpiSwitch PSE: Prostate cancer detection blood test that boosts PSA accuracy from 55% to 94%
- EpiSwitch CiRT
- EpiSwitch ME/CFS
- EpiSwitch Orion
- EpiSwitch Explorer
- EpiSwitch
Products and services
- EpiSwitch PSE (Prostate Screening EpiSwitch) Blood test administered alongside or following a standard PSA test to detect prostate cancer likelihood with 94% accuracy. Targets men being evaluated for prostate cancer by urologists, identifying those who require biopsy versus active surveillance.
- EpiSwitch CiRT (Checkpoint Inhibitor Response Test) First-of-its-kind blood test that predicts individual patient therapeutic response to immune checkpoint inhibitor immunotherapy with 85%+ accuracy. For oncologists and immunotherapists treating cancer patients with ICI therapies.
- EpiSwitch ME/CFS First-in-class blood test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome demonstrating 96% accuracy (92% sensitivity, 98% specificity) in detecting the condition. Targets ME/CFS patients and clinicians seeking reliable diagnostic tools for the disease.
- EpiSwitch Orion High-resolution 3D genomics research tool using AI algorithms and integrated Knowledge Graph to reveal how changes in DNA sequence affect 3D genome structure. For pharmaceutical researchers, biotech drug developers, and academic investigators identifying disease-driving targets and stratifying patients for precision medicine development.
- EpiSwitch Explorer Array Kit Array kit for 3D genomics research applications sold through the OBD online store. Targets researchers and academic institutions conducting 3D genomic analysis and biomarker discovery.
Quantifiable outcome
- EpiSwitch PSE boosts prostate cancer detection accuracy from 55% (PSA alone) to 94%
- +6 more outcomes
Companies that use Oxford Biodynamics
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles4 records
Oxford Biodynamics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Oxford Biodynamics partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered supporting, strategic and core.
- Google CloudsupportingOxford BioDynamics chair discussed key collaboration with Google Cloud for technology infrastructure and cloud computing capabilities.
- Foundation for the National Institutes of Health (FNIH)strategicReceived US FNIH grant to develop EpiSwitch immune health test for predicting patient responses to immune checkpoint inhibitor (ICI) cancer therapies. Test planned for US market launch in Q4 2021.
- PfizercoreOne of 40+ pharmaceutical and institutional partnerships. Collaborates on EpiSwitch 3D genomics platform for biomarker discovery and validation across multiple therapeutic areas.
- RochecorePharmaceutical partner in collaborative research using EpiSwitch platform for companion diagnostics and biomarker development.
- GenentechcorePharmaceutical partner utilizing EpiSwitch platform for biomarker research and patient stratification.
- EMD SeronocoreCollaborative research partner using EpiSwitch 3D genomics technology for drug development support.
- BiogencorePharmaceutical collaboration partner for biomarker discovery and validation using EpiSwitch platform.
- Mayo CliniccoreLeading US academic medical center collaborating on EpiSwitch technology validation and clinical research.
- Massachusetts General HospitalcorePremier US research hospital partner in collaborative studies using EpiSwitch 3D genomics platform.
- Mitsubishi Tanabe PharmacoreJapanese pharmaceutical company collaborating on EpiSwitch platform applications in drug development.
- Imperial College Healthcare NHS TrustcoreClinical validation partner for EpiSwitch PSE test through PROSTAGRAM trial. Embedded PSE into NHS workflow for prostate cancer screening evaluation.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
Oxford Biodynamics competitors and assessment
Company assessmentDirect peers
- Guardant Health: Leading liquid biopsy company offering blood-based cancer diagnostics for treatment selection and monitoring. Directly comparable as an oncology-focused molecular diagnostics peer with blood-based tests targeting similar physician customers in the US market.
- Natera: Cell-free DNA testing company with oncology (Signatera) and other blood-based diagnostic tests. Comparable in offering blood-based molecular diagnostics to oncologists and healthcare providers for treatment decisions and disease monitoring.
- Exact Sciences: Cancer screening and diagnostics company (Cologuard, Oncotype DX). Directly competes in blood-based and stool-based cancer screening markets with similar physician channels and payer coverage strategies as OBD's PSE prostate test.
- Veracyte: Genomic diagnostics company offering molecular tests for cancer diagnosis and treatment decisions. Comparable as a multi-indication genomic diagnostics platform with similar target customers (urologists, oncologists) and CLIA-certified lab operations.
- NeoGenomics: Oncology-focused clinical laboratory services and diagnostics company offering molecular and genetic testing. Comparable in providing specialty oncology diagnostics with similar hospital, oncologist, and pharma customer channels.
- Personalis: Cancer genomics company offering tumor profiling and molecular diagnostics for oncology treatment selection. Comparable in providing genomic biomarker services for pharma and biopharma companion diagnostic development.
- Angle plc: UK-based liquid biopsy company offering Parsortix CTC platform for cancer diagnostics and treatment monitoring. Comparable as a UK-listed small-cap molecular diagnostics peer pursuing similar oncology and pharma partnership channels.
Emerging players
- VolitionRx: Blood-based epigenetic diagnostics company developing Nu.Q cancer detection tests. Comparable as a small-cap blood-based epigenetic/3D genomics diagnostics peer pursuing cancer screening markets with similar commercial stage challenges.
Broad incumbents
- QIAGEN: Large molecular diagnostics tools and sample technologies company offering PCR, NGS, and biomarker solutions. Comparable as a broader molecular diagnostics infrastructure provider serving similar pharma and clinical research customers with a wider portfolio.
- Bio-Techne: Life sciences tools and diagnostics company providing reagents, assays, and biomarker analysis platforms. Comparable as an established player offering biomarker discovery and validation tools to pharma and academic researchers, overlapping with OBD's EpiSwitch Explorer and Orion research offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Oxford Biodynamics social profiles
Digital presenceOxford Biodynamics compliance and trust
Trust signalCompliance4 records
Oxford Biodynamics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxford Biodynamics leadership team
Management profileNumber of profiles
Profiles8 records
Oxford Biodynamics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Oxford Biodynamics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxford Biodynamics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxford Biodynamics
What does Oxford Biodynamics do?
Oxford BioDynamics develops and commercializes clinical diagnostic tests based on its proprietary EpiSwitch 3D genomics platform, which measures chromatin conformation signatures in blood samples to predict cancer likelihood, immunotherapy response, and disease diagnosis. The company sells blood-based diagnostic tests (EpiSwitch PSE, CiRT, ME/CFS) to healthcare providers and offers research tools (EpiSwitch Orion, Explorer Array Kit) for pharmaceutical and academic partners.
Is Oxford Biodynamics a public or private company?
Oxford Biodynamics is a public company. It is classified as public and is currently operating.
When was Oxford Biodynamics founded?
Oxford Biodynamics was founded in 2007. It employs 51 to 100 people.
Where is Oxford Biodynamics based?
Oxford Biodynamics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Oxford Biodynamics make money?
Three revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are pharmaceutical Partnerships and research Tools and Services.
Who are Oxford Biodynamics's main competitors?
Direct peers on record are Guardant Health, Natera, Exact Sciences, Veracyte, NeoGenomics, Personalis and Angle plc. VolitionRx is listed as an emerging player. Broad incumbents are QIAGEN and Bio-Techne.
Does Oxford Biodynamics have an API?
No public API is recorded for Oxford Biodynamics.
What industry is Oxford Biodynamics in?
Oxford Biodynamics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAFAMAJ, Reference & Esoteric Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.